The mapping of the human genome then opened up an era of precision medicine, as whole-genome sequencing revealed mutations that could be directly targeted. Not long ago, a diagnosis of advanced cancer left doctors with little more than symptom control and hope. Over the course of a few of decades, however, that picture changed dramatically. Chemotherapy delivered the first meaningful survival gains, though at a steep cost in side effects, a cost later softened by a new generation of supportive drugs that made treatment safer and more tolerable. Survival improved again, but a cure remained elusive: tumours kept finding new, resistant mutations to evade each targeted drug. It took a deeper understanding of the immune system to breach the next frontier: immunotherapy taught the body’s own defences to attack cancers once thought untreatable.
The results were striking: the combination significantly improved both recurrence-free and distant metastasis-free survival compared with pembrolizumab alone. The current moment resembles the early days of immunotherapy. When checkpoint inhibitors first showed unprecedented benefit in melanoma, many assumed the impact would stay confined to a handful of cancers. Instead, immunotherapy became a universal oncology platform, transforming treatment across tumour types. If these trials succeed, the implications could be enormous. Future treatment may routinely involve genomic sequencing after surgery, followed by the rapid design of a patient-specific vaccine given alongside immunotherapy — aiming to wipe out microscopic residual disease before it can return. This is the essence of personalised cancer treatment. Together, these advances are moving personalised cancer vaccines from concept to clinical reality.
Earlier studies of the same strategy had already shown roughly a 49% reduction in the risk of recurrence or death, and a 59% reduction in the risk of distant metastasis or death, compelling evidence that a personalised vaccine can amplify the effect of existing immunotherapy. Further automation of neoantigen discovery through AI and manufacturing techniques refined during the COVID-19 pandemic have demonstrated the capacity to generate sophisticated mRNA therapies at scale.
Now, a new contender has emerged that could rewrite the story once more: personalized mRNA tumour vaccines . Recent trial results suggest that the next chapter of the cancer treatment story may already be unfolding. They received either immunotherapy through pembrolizumab alone, or pembrolizumab combined with an individualised vaccine designed, using artificial intelligence, from the genetic profile of each patient’s own tumour. This vaccine essentially trained the patients’ immune systems to recognise and destroy unique mutations (neoantigens) on their tumour cells
The recent excitement around mRNA vaccines stems from the Phase III INTerpath-001 trial , which evaluated intismeran autogene (mRNA-4157/V940), a personalised mRNA vaccine. The study enrolled roughly 1,100 patients with high-risk melanoma who had undergone complete surgical removal of visible disease.
